Format

Send to

Choose Destination
Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Author information

1
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands a.hagenbeek@amc.nl.
2
Department of Hematology, Amsterdam UMC, University of Amsterdam, the Netherlands.
3
Department of Hematology, Amsterdam UMC, Vrije Universiteit, the Netherlands.
4
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
5
Department of Hematology, University Medical Center Groningen, the Netherlands.
6
Lymphoma and Myeloma Center Amsterdam (LYMMCARE), the Netherlands.
7
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.
8
Biometric Department, NKI-AVL, Amsterdam, the Netherlands.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center